A company insider recently sold 3,479 shares of Karyopharm Therapeutics Inc. [KPTI]. Should You Sale?

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Karyopharm Therapeutics Inc. shares valued at $18,196 were sold by Paulson Richard A. on Sep 08. At $5.23 per share, Paulson Richard A. sold 3,479 shares. The insider’s holdings dropped to 622,998 shares worth approximately $2.87 million following the completion of this transaction.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Also, Paulson Richard A. sold 2,314 shares, netting a total of over 10,367 in proceeds. Following the sale of shares at $4.48 each, the insider now holds 626,477 shares.

Before that, Paulson Richard A. had sold 2,115 shares from its account. In a trade valued at $10,948, the President and CEO traded Karyopharm Therapeutics Inc. shares for $5.18 each. Upon closing the transaction, the insider’s holdings decreased to 2,115 shares, worth approximately $2.9 million.

As published in a research note from JP Morgan on February 09, 2022, Karyopharm Therapeutics Inc. [KPTI] has been rated up from an Underweight to a Neutral and the price target has been revised to $8. This represents a 42.37% premium over Thursday’s closing price. As of August 06, 2021, SVB Leerink has decreased its “an Outperform” rating to a “Mkt perform” for KPTI. Earlier on August 06, 2021, RBC Capital Mkts downgraded its rating. Their new recommendation was “a Sector perform” for KPTI stock which previously was a “an Outperform”.

Analyzing KPTI’s Price Performance

On Thursday, Karyopharm Therapeutics Inc. [NASDAQ: KPTI] plunged -1.07% to $4.61. The stock’s lowest price that day was $4.42, but it reached a high of $4.68 in the same session. During the last five days, there has been a drop of approximately -10.83%. Over the course of the year, Karyopharm Therapeutics Inc. shares have dropped approximately -28.30%. Shares of the company reached a 52-week high of $14.73 on 02/18/22 and a 52-week low of $4.00 on 08/02/22. A 50-day SMA is recorded $4.97, while a 200-day SMA reached $6.51. Nevertheless, trading volume fell to 1.32 million shares from 1.17 million shares the previous day.

Support And Resistance Levels for Karyopharm Therapeutics Inc. (KPTI)

According to the 24-hour chart, there is a support level at 4.46, which, if violated, would cause prices to drop to 4.31. In the upper region, resistance lies at 4.72. The next price resistance is at 4.83. RSI (Relative Strength Index) is 39.58 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.31, which suggests the price will decrease in the coming days. Percent R is at 81.90%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Karyopharm Therapeutics Inc. subject to short interest?

Stocks of Karyopharm Therapeutics Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 2.73 million shares to 18.08 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 15.35 million shares. A jump of 15.1% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.98 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.98.

Which companies own the most shares of Karyopharm Therapeutics Inc. (KPTI)?

According to SSgA Funds Management, Inc. filings, the company currently owns 10,362,009 shares, which is about 12.98% of the total KPTI shares outstanding. The investor’s shares have plunged by -604,692 from its previous 13-F filing of 10966701.0 shares. With the completion of the buy transaction, BlackRock Fund Advisors’s stake is now worth $30,712,186. A total of 268,364 shares of Karyopharm Therapeutics Inc. were bought by The Vanguard Group, Inc. during the quarter, and -1,625,443 were sold by Commodore Capital LP. In its current portfolio, Walleye Capital LLC holds 1,745,415 shares valued at $8.83 million.

In terms of Karyopharm Therapeutics Inc. share price expectations, FactSet research, analysts set an average price target of $9.56 in the next 12 months, up nearly 50.21% from the previous closing price of $4.66. Analysts anticipate Karyopharm Therapeutics Inc. stock to reach $18.00 by 2022, with the lowest price target being $5.00. In spite of this, 9 analysts ranked Karyopharm Therapeutics Inc. stock as an Overweight at the end of 2022.


Please enter your comment!
Please enter your name here